On October 13, local time, Darei Biotech announced that it has granted Roche an exclusive global license for its RNAi candidate drug under development targeting activin receptor-like kinase 7. The drug candidate is developed based on Darex Biotech's proprietary extra-hepatic delivery platform technology. Under the terms of the agreement, Darex Biotech will receive a down payment of up to $100 million and recent milestone payments, as well as be eligible for development, registration and commercialization milestone payments of up to $1.06 billion, and can receive tiered royalties based on global net sales.
Zhitongcaijing · 2d ago
Share
Listen to the news
On October 13, local time, Darei Biotech announced that it has granted Roche an exclusive global license for its RNAi candidate drug under development targeting activin receptor-like kinase 7. The drug candidate is developed based on Darex Biotech's proprietary extra-hepatic delivery platform technology. Under the terms of the agreement, Darex Biotech will receive a down payment of up to $100 million and recent milestone payments, as well as be eligible for development, registration and commercialization milestone payments of up to $1.06 billion, and can receive tiered royalties based on global net sales.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending